×
Doge reportedly using AI tool to create ‘delete list’ of federal regulations

Doge reportedly using AI tool to create ‘delete list’ of federal regulations

The “department of government efficiency” (Doge) is using artificial intelligence to create a “delete list” of federal regulations, according to a report, proposing to use the tool to cut 50% of regulations by the first anniversary of Donald Trump’s second inauguration.

The “Doge AI Deregulation Decision Tool” will analyze 200,000 government regulations, according to internal documents obtained by the Washington Post, and select those which it deems to be no longer required by law.

Doge, which was run by Elon Musk until May, claims that 100,000 of those regulations can then be eliminated, following some staff feedback.

A PowerPoint presentation made public by the Post claims that the Department of Housing and Urban Development (HUD) used the AI tool to make “decisions on 1,083 regulatory sections”, while the Consumer Financial Protection Bureau used it to write “100% of deregulations”.

The Post spoke to three HUD employees who told the newspaper AI had been “recently used to review hundreds, if not more than 1,000, lines of regulations”.

During his 2024 campaign, Donald Trump claimed that government regulations were “driving up the cost of goods” and promised the “most aggressive regulatory reduction” in history. He repeatedly criticized rules which aimed to tackle the climate crisis, and as president he ordered the heads of all government agencies to undertake a review of all regulations in coordination with Doge.

Asked about the use of AI in deregulation by the Post, White House spokesperson Harrison Fields said “all options are being explored” to achieve the president’s deregulation promises. Fields said that “no single plan has been approved or green-lit”, and the work is “in its early stages and is being conducted in a creative way in consultation with the White House”.

Fields added: “The Doge experts creating these plans are the best and brightest in the business and are embarking on a never-before-attempted transformation of government systems and operations to enhance efficiency and effectiveness.”

Musk appointed a slew of inexperienced staffers to Doge, including Edward Coristine, a 19-year-old who was previously known by the online handle “Big Balls”. Earlier this year, Reuters reported that Coristine was one of two Doge associates promoting the use of AI across the federal bureaucracy.

Source link
#Doge #reportedly #tool #create #delete #list #federal #regulations

ASUS Chromebook CM32 Detachable Leads the Lineup
ASUS Expands Chromebook Lineup in India With New CM14, CM15, and CM32 Models
	
Chromebooks aren’t exactly the most exciting laptops on the market, but they continue to be a popular option for students and anyone who primarily works in the cloud. Looking to capitalize on that demand, ASUS has launched three new Chromebooks in India, including a detachable 2-in-1 model that doubles as a tablet.



The new lineup consists of the ASUS Chromebook CM32 Detachable, Chromebook CM14, and Chromebook CM15. All three devices run ChromeOS and come with Google’s latest AI-powered features, along with cloud-first productivity tools aimed at students, educators, and young professionals. ASUS is also bundling three months of Google AI Pro with the devices, giving buyers access to Google’s AI tools and 5TB of cloud storage.



ASUS Chromebook CM32 Detachable Leads the Lineup







Leading the lineup is the ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.



ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.



Chromebook CM14 and CM15 Focus on Battery Life







If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.



One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.



Price and Availability



The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.





#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus

Leading the lineup is the ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.

ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.

Chromebook CM14 and CM15 Focus on Battery Life

If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.

One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.

Price and Availability

The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.

#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus">ASUS Expands Chromebook Lineup in India With New CM14, CM15, and CM32 Models
	
Chromebooks aren’t exactly the most exciting laptops on the market, but they continue to be a popular option for students and anyone who primarily works in the cloud. Looking to capitalize on that demand, ASUS has launched three new Chromebooks in India, including a detachable 2-in-1 model that doubles as a tablet.



The new lineup consists of the ASUS Chromebook CM32 Detachable, Chromebook CM14, and Chromebook CM15. All three devices run ChromeOS and come with Google’s latest AI-powered features, along with cloud-first productivity tools aimed at students, educators, and young professionals. ASUS is also bundling three months of Google AI Pro with the devices, giving buyers access to Google’s AI tools and 5TB of cloud storage.



ASUS Chromebook CM32 Detachable Leads the Lineup







Leading the lineup is the ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.



ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.



Chromebook CM14 and CM15 Focus on Battery Life







If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.



One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.



Price and Availability



The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.





#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus

ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.

ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.

Chromebook CM14 and CM15 Focus on Battery Life

If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.

One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.

Price and Availability

The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.

#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus">ASUS Expands Chromebook Lineup in India With New CM14, CM15, and CM32 Models

Chromebooks aren’t exactly the most exciting laptops on the market, but they continue to be a popular option for students and anyone who primarily works in the cloud. Looking to capitalize on that demand, ASUS has launched three new Chromebooks in India, including a detachable 2-in-1 model that doubles as a tablet.

The new lineup consists of the ASUS Chromebook CM32 Detachable, Chromebook CM14, and Chromebook CM15. All three devices run ChromeOS and come with Google’s latest AI-powered features, along with cloud-first productivity tools aimed at students, educators, and young professionals. ASUS is also bundling three months of Google AI Pro with the devices, giving buyers access to Google’s AI tools and 5TB of cloud storage.

ASUS Chromebook CM32 Detachable Leads the Lineup

ASUS Expands Chromebook Lineup in India With New CM14, CM15, and CM32 Models
	
Chromebooks aren’t exactly the most exciting laptops on the market, but they continue to be a popular option for students and anyone who primarily works in the cloud. Looking to capitalize on that demand, ASUS has launched three new Chromebooks in India, including a detachable 2-in-1 model that doubles as a tablet.



The new lineup consists of the ASUS Chromebook CM32 Detachable, Chromebook CM14, and Chromebook CM15. All three devices run ChromeOS and come with Google’s latest AI-powered features, along with cloud-first productivity tools aimed at students, educators, and young professionals. ASUS is also bundling three months of Google AI Pro with the devices, giving buyers access to Google’s AI tools and 5TB of cloud storage.



ASUS Chromebook CM32 Detachable Leads the Lineup







Leading the lineup is the ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.



ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.



Chromebook CM14 and CM15 Focus on Battery Life







If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.



One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.



Price and Availability



The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.





#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus

Leading the lineup is the ASUS Chromebook CM32, a 2-in-1 device designed for users who want the flexibility of both a tablet and a laptop. The device features a 2.5K touchscreen display, a detachable keyboard, a magnetic kickstand, and support for the ASUS Pen. This makes it suitable for everything from note-taking and studying to media consumption and light gaming.

ASUS has also focused on portability and durability. Despite its lightweight design, the Chromebook comes with military-grade durability certifications and Corning Gorilla Glass protection, making it better equipped to handle everyday wear and tear.

Chromebook CM14 and CM15 Focus on Battery Life

If you prefer a traditional laptop design, ASUS is also offering the Chromebook CM14 and Chromebook CM15. The two laptops feature 14-inch and 15-inch displays, respectively, and are powered by the MediaTek Kompanio 540 processor. While these aren’t performance-focused machines, they should be more than capable of handling web browsing, document editing, online classes, and other everyday workloads.

One of the standout features is battery life. ASUS claims both laptops can deliver up to 20 hours of usage on a single charge, which should easily get most users through a full day of work or study. The laptops also include a 180-degree hinge, allowing users to lay the display flat for easier collaboration during meetings, presentations, or classroom sessions.

Price and Availability

The new ASUS Chromebook lineup is now available through Amazon and the ASUS eShop. Pricing starts at ₹26,990 for the Chromebook CM14, while the larger Chromebook CM15 starts at ₹28,990. The more premium Chromebook CM32 Detachable is priced at ₹37,990. ASUS is also offering No Cost EMI and ASUS Easy Pay financing options. Monthly installments start at ₹5,165 for the CM14, ₹5,665 for the CM15, and ₹6,332 for the CM32 Detachable.

#ASUS #Expands #Chromebook #Lineup #India #CM14 #CM15 #CM32 #ModelsAsus

published late last week in the journal Nature Microbiology.

Good guy prions?

Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.

Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.

According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.

The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations).

Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections.

The researchers have coined these antibacterial fragments collected from prions as “prionins.”

The future of prionins

More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body.

At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing.

“For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”

With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.

#Deadly #Proteins #Mad #Cow #Disease #Fight #Superbugsantibiotic resistance,experimental drugs,prions">Deadly Proteins Behind Mad Cow Disease Might Help Us Fight Superbugs
                The next frontier of antibiotics might come from an unexpected place. Recent research identifies potential antibiotic candidates from inside prions—proteins capable of causing some of the deadliest brain infections ever known, such as mad cow disease.

 Scientists at the University of Pennsylvania used artificial intelligence to rapidly search hundreds of prions and prion-like proteins for peptides with antibacterial activity. They found several dozen promising candidates, two of which have already shown results treating bacterial infections in mice. The team’s findings establish “prion-related proteins as a productive source space for antibiotic discovery,” the scientists wrote in their paper, published late last week in the journal Nature Microbiology.

 Good guy prions? Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.

 Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.   According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.

 The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations). Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections. The researchers have coined these antibacterial fragments collected from prions as “prionins.”

 The future of prionins More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body. At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing. “For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”

 With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.      #Deadly #Proteins #Mad #Cow #Disease #Fight #Superbugsantibiotic resistance,experimental drugs,prions

published late last week in the journal Nature Microbiology.

Good guy prions?

Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.

Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.

According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.

The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations).

Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections.

The researchers have coined these antibacterial fragments collected from prions as “prionins.”

The future of prionins

More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body.

At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing.

“For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”

With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.

#Deadly #Proteins #Mad #Cow #Disease #Fight #Superbugsantibiotic resistance,experimental drugs,prions">Deadly Proteins Behind Mad Cow Disease Might Help Us Fight SuperbugsDeadly Proteins Behind Mad Cow Disease Might Help Us Fight Superbugs
                The next frontier of antibiotics might come from an unexpected place. Recent research identifies potential antibiotic candidates from inside prions—proteins capable of causing some of the deadliest brain infections ever known, such as mad cow disease.

 Scientists at the University of Pennsylvania used artificial intelligence to rapidly search hundreds of prions and prion-like proteins for peptides with antibacterial activity. They found several dozen promising candidates, two of which have already shown results treating bacterial infections in mice. The team’s findings establish “prion-related proteins as a productive source space for antibiotic discovery,” the scientists wrote in their paper, published late last week in the journal Nature Microbiology.

 Good guy prions? Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.

 Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.   According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.

 The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations). Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections. The researchers have coined these antibacterial fragments collected from prions as “prionins.”

 The future of prionins More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body. At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing. “For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”

 With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.      #Deadly #Proteins #Mad #Cow #Disease #Fight #Superbugsantibiotic resistance,experimental drugs,prions

The next frontier of antibiotics might come from an unexpected place. Recent research identifies potential antibiotic candidates from inside prions—proteins capable of causing some of the deadliest brain infections ever known, such as mad cow disease.

Scientists at the University of Pennsylvania used artificial intelligence to rapidly search hundreds of prions and prion-like proteins for peptides with antibacterial activity. They found several dozen promising candidates, two of which have already shown results treating bacterial infections in mice.

The team’s findings establish “prion-related proteins as a productive source space for antibiotic discovery,” the scientists wrote in their paper, published late last week in the journal Nature Microbiology.

Good guy prions?

Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.

Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.

According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.

The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations).

Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections.

The researchers have coined these antibacterial fragments collected from prions as “prionins.”

The future of prionins

More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body.

At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing.

“For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”

With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.

#Deadly #Proteins #Mad #Cow #Disease #Fight #Superbugsantibiotic resistance,experimental drugs,prions

Post Comment